Long Rong, Guo Hao, Chen Kun
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, 445000, Hubei, China.
Sci Rep. 2025 Feb 21;15(1):6429. doi: 10.1038/s41598-025-90960-x.
The phase III NOTABLE trial has revealed that nimotuzumab plus gemcitabine achieves greater clinical benefit in the first-line treating K-Ras wild type locally advanced (LA) or metastatic pancreatic cancer (mPC), compared to gemcitabine. Hence, herein, we examined the cost-efficiency of introducing nimotuzumab to gemcitabine, relative to gemcitabinealone, in first-line K-Ras wild type LA or mPC therapy from a Chinese payer perspective. We generated an exhaustive decision-analytical Markov model using three exclusive health states to incorporate both clinical and economic consequences of nimotuzumab plus gemcitabine versus gemcitabine alone as first-line therapy patients with K-Ras wild type LA or mPC. Using a 10-year lifetime horizon, we assessed the total medical expenditure, quality-adjusted life years (QALYs), and incremental cost‒effectiveness ratio (ICER) as the primary surrogate outcomes of our model. Sensitivity analyses were conducted via alteration of internally tweakable parameters, and further subgroup analyses were conducted as needed. The overall health surrogate outcomes were 2.94 QALYs ($215,799) among patients with nimotuzumab plus gemcitabine and 1.83 QALYs ($86,039) among patients with gemcitabine alone (ICER value, $117,263/QALY; Incremental net health benefit [INHB] value, - 2.46/QALY). Based on our sensitivity analysis, among all parameters, progression-free survival (PFS) utility was of utmost importance, and it exerted a considerable impact on our model. The ICER consistently well exceeded the willingness-to-pay (WTP) threshold and negative INHBs were observed across all patient subcategories with zero alteration recorded as cost-effective in the subgroup analyses. Nimotuzumab plus gemcitabine, relative to gemcitabine alone, is not a cost-effective first-line treatment among patients with K-Ras wild type LA or mPC at the current prices offered in China.
III期NOTABLE试验显示,与吉西他滨相比,尼妥珠单抗联合吉西他滨在一线治疗K-Ras野生型局部晚期(LA)或转移性胰腺癌(mPC)中取得了更大的临床益处。因此,在本文中,我们从中国支付方的角度,研究了在一线K-Ras野生型LA或mPC治疗中,相对于单用吉西他滨,将尼妥珠单抗引入吉西他滨治疗的成本效益。我们使用三种互斥的健康状态生成了一个详尽的决策分析马尔可夫模型,以纳入尼妥珠单抗联合吉西他滨与单用吉西他滨作为一线治疗K-Ras野生型LA或mPC患者的临床和经济后果。以10年的生存期为时间跨度,我们评估了总医疗支出、质量调整生命年(QALY)和增量成本效益比(ICER),作为我们模型的主要替代结局。通过改变内部可调整参数进行敏感性分析,并根据需要进行进一步的亚组分析。总体健康替代结局在接受尼妥珠单抗联合吉西他滨治疗的患者中为2.94个QALY(215,799美元),在单用吉西他滨治疗的患者中为1.83个QALY(86,039美元)(ICER值为117,263美元/QALY;增量净健康效益[INHB]值为-2.46/QALY)。基于我们的敏感性分析,在所有参数中,无进展生存期(PFS)效用最为重要,并且对我们的模型产生了相当大的影响。ICER始终远远超过支付意愿(WTP)阈值,并且在所有患者亚组中均观察到负的INHB,在亚组分析中,零变化被记录为具有成本效益。相对于单用吉西他滨,按照中国目前提供的价格,尼妥珠单抗联合吉西他滨在K-Ras野生型LA或mPC患者中并非具有成本效益的一线治疗方案。